Brief: Pharming Group Announces Updated Full Year 2023 Guidance And Joenja U.S. Launch Update

Pharming

08/01/2024 06:16

Jan 8 (Reuters) - Pharming Group NV  PHAR.AS :
    * PHARMING GROUP ANNOUNCES UPDATED FULL YEAR 2023 GUIDANCE
AND
JOENJA® U.S. LAUNCH UPDATE
    * EXPECT 10% GROWTH IN RUCONEST® REVENUE, SIGNIFICANTLY
EXCEEDING
PRIOR GUIDANCE
    * EXPECT JOENJA® REVENUES OF APPROXIMATELY US$18 MILLION
WITH 81
PATIENTS ON PAID THERAPY AT YEAR END
    * JOENJA: COMPLETION OF THESE STUDIES IS EXPECTED DURING 4Q
2024
    * FOR FULL YEAR 2023, TOTAL REVENUES ARE EXPECTED TO
INCREASE BY
19% TO APPROXIMATELY US$245 MILLION (PRELIMINARY AND UNAUDITED*)
    * PRELIMINARY, UNAUDITED CASH AND CASH EQUIVALENTS, TOGETHER
WITH
RESTRICTED CASH AND MARKETABLE SECURITIES, ARE EXPECTED TO TOTAL
US$215.0 MILLION AT END OF 2023
    * HAS NOT COMPLETED ITS FINANCIAL CLOSING PROCEDURES FOR
QUARTER
OR YEAR ENDED DECEMBER 31, 2023 AND ACTUAL RESULTS COULD DIFFER
FROM THESE PRELIMINARY FINANCIAL RESULTS

Source text for Eikon:  ID:nGNE2B9c09 
Further company coverage:  PHAR.AS 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))